US › Healthcare

National Research Corp (NRC)

US · Healthcare · Health Information Services

$19.59+0.46%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$35.4M
Revenue YoY
+4.0%
Net profit
$-3.3M
Profit YoY
-2997.2%
EPS
$0.31
EPS estimate
$0.14
Net margin
-9.3%

EPS came in at 0.31 against a street estimate of 0.14 — a beat of 121.4%.

Key statistics

Market cap
$431.9M
P/E
81.3
Forward P/E
17.2
P/B
65.94
Book value
$0.62
EPS (TTM)
$0.24
Dividend yield
3.17%
52-week high
$23.68
52-week low
$10.74
50-day MA
$20.39
200-day MA
$17.58
Beta
0.38

Analyst view

Analysts rate National Research Corp a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $26.00.

Shareholding

Insiders
49.74%
Institutions
52.29%

Largest institutional holders

FundStake
Kayne Anderson Rudnick Investment Management LLC11.91%
Morgan Stanley - Brokerage Accounts4.53%
BlackRock Inc4.41%
Vanguard Capital Management, LLC2.99%
Dimensional Fund Advisors, Inc.2.21%
Geode Capital Management, LLC1.78%
QV Investors Inc1.72%
Renaissance Technologies Corp1.54%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for National Research Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.